Status:
COMPLETED
Pathogenic Variants in Homologous Recombination Repair Genes in Patients With Epithelial Ovarian Cancer
Lead Sponsor:
Hellenic Cooperative Oncology Group
Conditions:
Epithelial Ovarian Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
Molecular alterations in Homologous Recombination Repair (HRR) genes have been associated with clinical benefit from chemotherapy and/or Poly (ADP-ribose) polymerase (PARP) inhibitors in patients with...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Diagnosed with epithelial ovarian cancer
- Received treatment at HeCOG-affiliated institutions
- Have signed informed consent
- With adequate tumor tissue for analysis
Exclusion
Key Trial Info
Start Date :
January 1 2004
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
550 Patients enrolled
Trial Details
Trial ID
NCT04716374
Start Date
January 1 2004
End Date
December 1 2019
Last Update
January 20 2021
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.